Kaken Pharmaceutical Co(KKPCF)
$23.90-0.05 (-0.23%)
KKPCF
Kaken Pharmaceutical Co financials statements
$23.90
At close:-0.05 (-0.23%)
Kaken Pharmaceutical Co (KKPCF) Ratios
4 Followers
Kaken Pharmaceutical Co Ratios
KKPCF's free cash flow for Q1 2026 was ¥0.00. For the 2026 fiscal year, KKPCF's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.67 | 4.52 | 5.62 | 5.27 | 5.81 |
| Quick Ratio | 3.04 | 3.60 | 4.72 | 4.53 | 5.02 |
| Cash Ratio | 1.78 | 2.15 | 2.66 | 2.86 | 3.20 |
| Solvency Ratio | 0.44 | 0.18 | 0.39 | 0.27 | 0.45 |
| Operating Cash Flow Ratio | 0.98 | -0.53 | 0.14 | 0.44 | 0.70 |
| Short-Term Operating Cash Flow Coverage | 7.74 | -2.88 | 0.67 | 2.40 | 3.46 |
| Net Current Asset Value | ¥ 73.59B | ¥ 63.46B | ¥ 79.11B | ¥ 80.41B | ¥ 83.75B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Debt-to-Equity Ratio | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Debt-to-Capital Ratio | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.25 | 1.21 | 1.19 | 1.22 | 1.20 |
| Debt Service Coverage Ratio | 4.26 | 1.42 | 2.79 | 2.08 | 3.12 |
| Interest Coverage Ratio | 751.29 | -19.98 | 559.59 | 470.47 | 1003.76 |
| Debt to Market Cap | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 |
| Interest Debt Per Share | 101.62 | 102.74 | 102.47 | 102.93 | 101.82 |
| Net Debt to EBITDA | -2.28 | -7.19 | -3.72 | -5.93 | -3.49 |
| Profitability Margins | |||||
| Gross Profit Margin | 61.96% | 51.05% | 53.49% | 54.20% | 54.68% |
| EBIT Margin | 20.70% | 3.07% | 13.62% | 9.36% | 18.29% |
| EBITDA Margin | 23.42% | 7.39% | 17.45% | 12.88% | 21.55% |
| Operating Profit Margin | 22.37% | -1.17% | 13.20% | 10.96% | 22.44% |
| Pretax Profit Margin | 20.67% | 3.01% | 13.60% | 9.34% | 18.26% |
| Net Profit Margin | 14.83% | 2.79% | 11.14% | 7.45% | 12.56% |
| Continuous Operations Profit Margin | 14.83% | 2.79% | 11.14% | 7.45% | 12.56% |
| Net Income Per EBT | 71.75% | 92.69% | 81.92% | 79.80% | 68.77% |
| EBT Per EBIT | 92.39% | -257.29% | 102.97% | 85.23% | 81.37% |
| Return on Assets (ROA) | 7.32% | 1.20% | 4.68% | 3.27% | 5.78% |
| Return on Equity (ROE) | 9.14% | 1.45% | 5.58% | 3.99% | 6.93% |
| Return on Capital Employed (ROCE) | 13.14% | -0.57% | 6.23% | 5.50% | 11.68% |
| Return on Invested Capital (ROIC) | 9.21% | -0.52% | 4.98% | 4.27% | 7.82% |
| Return on Tangible Assets | 8.15% | 1.39% | 4.89% | 3.41% | 6.08% |
| Earnings Yield | 8.15% | 1.37% | 6.13% | 3.92% | 6.46% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.44 | 3.38 | 3.03 | 3.79 | 3.75 |
| Payables Turnover | 4.30 | 4.97 | 4.72 | 5.45 | 5.80 |
| Inventory Turnover | 1.88 | 1.97 | 1.95 | 2.15 | 2.30 |
| Fixed Asset Turnover | 3.40 | 2.83 | 2.84 | 2.86 | 2.95 |
| Asset Turnover | 0.49 | 0.43 | 0.42 | 0.44 | 0.46 |
| Working Capital Turnover Ratio | 1.11 | 1.00 | 0.81 | 0.81 | 0.83 |
| Cash Conversion Cycle | 191.36 | 220.03 | 229.98 | 199.36 | 193.03 |
| Days of Sales Outstanding | 82.20 | 108.01 | 120.30 | 96.36 | 97.26 |
| Days of Inventory Outstanding | 194.07 | 185.40 | 187.02 | 169.93 | 158.68 |
| Days of Payables Outstanding | 84.91 | 73.39 | 77.34 | 66.93 | 62.91 |
| Operating Cycle | 276.27 | 293.42 | 307.31 | 266.29 | 255.94 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 780.36 | -292.23 | 68.29 | 246.28 | 351.15 |
| Free Cash Flow Per Share | 671.92 | -371.26 | 10.86 | 187.56 | 265.39 |
| Dividend Paid and CapEx Coverage Ratio | 2.63 | -1.17 | 0.33 | 1.18 | 1.49 |
| Capital Expenditure Coverage Ratio | 7.20 | -3.70 | 1.19 | 4.19 | 4.09 |
| Operating Cash Flow Coverage Ratio | 7.74 | -2.88 | 0.67 | 2.40 | 3.46 |
| Operating Cash Flow to Sales Ratio | 0.32 | -0.14 | 0.04 | 0.13 | 0.18 |
| Free Cash Flow Yield | 14.99% | -8.97% | 0.31% | 5.08% | 6.82% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 12.26 | 73.21 | 16.30 | 25.52 | 15.47 |
| Price-to-Sales (P/S) Ratio | 1.82 | 2.04 | 1.82 | 1.90 | 1.94 |
| Price-to-Book (P/B) Ratio | 1.12 | 1.06 | 0.91 | 1.02 | 1.07 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 6.67 | -11.15 | 319.11 | 19.70 | 14.66 |
| Price-to-Operating Cash Flow Ratio | 5.74 | -14.17 | 50.77 | 15.00 | 11.08 |
| Price-to-Earnings Growth (PEG) Ratio | 0.17 | -0.87 | 0.35 | -0.60 | -0.56 |
| Enterprise Value Multiple | 5.48 | 20.43 | 6.69 | 8.84 | 5.53 |
| Enterprise Value | 120.76B | 116.09B | 84.06B | 83.11B | 90.56B |
| EV to EBITDA | 5.48 | 20.43 | 6.69 | 8.84 | 5.53 |
| EV to Sales | 1.28 | 1.51 | 1.17 | 1.14 | 1.19 |
| EV to Free Cash Flow | 4.71 | -8.25 | 205.02 | 11.79 | 8.98 |
| EV to Operating Cash Flow | 4.06 | -10.48 | 32.62 | 8.98 | 6.79 |
| Tangible Book Value Per Share | 3494.26 | 3253.12 | 3611.65 | 3462.62 | 3425.33 |
| Shareholders’ Equity Per Share | 3999.63 | 3893.77 | 3809.39 | 3626.65 | 3626.97 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.28 | 0.07 | 0.18 | 0.20 | 0.31 |
| Revenue Per Share | 2464.10 | 2027.64 | 1909.11 | 1942.56 | 2002.05 |
| Net Income Per Share | 365.42 | 56.55 | 212.66 | 144.79 | 251.44 |
| Tax Burden | 0.72 | 0.93 | 0.82 | 0.80 | 0.69 |
| Interest Burden | 1.00 | 0.98 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.20 | 0.27 | 0.17 | 0.22 | 0.11 |
| SG&A to Revenue | 0.20 | 0.25 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 2.14 | -5.17 | 0.32 | 1.36 | 0.96 |
Currency in JPY

